相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。From Pure Antagonists to Pure Degraders of the Estrogen Receptor: Evolving Strategies for the Same Target
Madhusoodanan Mottamal et al.
ACS OMEGA (2021)
Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents
Guangdi Wang
TRANSLATIONAL CANCER RESEARCH (2020)
ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models
Shanchun Guo et al.
Oncotarget (2018)
Rational Design of a Boron-Modified Triphenylethylene (GLL398) as an Oral Selective Estrogen Receptor Downregulator
Jiawang Liu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Metabolism, pharmacokinetics, and bioavailability of ZB716, a Steroidal Selective Estrogen Receptor Downregulator (SERD)
Changde Zhang et al.
ONCOTARGET (2017)
Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD)
Jiawang Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
A Good Drug Made Better: The Fulvestrant Dose-Response Story
John F. R. Robertson et al.
CLINICAL BREAST CANCER (2014)
Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial
Angelo Di Leo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Boron-Based 4-Hydroxytamoxifen Bioisosteres for Treatment of de Novo Tamoxifen Resistant Breast Cancer
Quan Jiang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue
S Chouinard et al.
MOLECULAR PHARMACOLOGY (2006)
Fulvestrant: pharmacokinetics and pharmacology
JFR Robertson et al.
BRITISH JOURNAL OF CANCER (2004)
分享论文
